EZH2 and ovarian cancer: These data revealed that a high expression of EZH2 [OS: hazard ratio (HR) = 1.851, 95% CI = 1.240–2.689, p = 0.0027; progression-free survival (DFS): HR = 1.733, 95% CI = 1.152–2.516, p = 0.0083] (Figures 5C,D) and a low expression of CYP27B1 (OS: HR = 1.645, 95% CI = 1.153–2.520, p = 0.0082; DFS: HR = 1.674, 95% CI = 1.175–2.573, p = 0.0062) (Figures 5E,F) were associated with poor prognosis in patients with ovarian cancer.